Expanding the use of arsenic trioxide: Leukemias and beyond
- 1 April 2002
- journal article
- review article
- Published by Elsevier BV in Seminars in Hematology
- Vol. 39 (2), 22-26
- https://doi.org/10.1053/shem.2002.33611
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic LeukemiaJournal of Clinical Oncology, 2001
- Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosageLeukemia, 2001
- Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivoBlood, 2001
- Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.Seminars in Hematology, 2001
- Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesisBlood, 2000
- Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia PatientsBlood, 1999
- Malignant Cells Can Be Sensitized to Undergo Growth Inhibition and Apoptosis by Arsenic Trioxide Through Modulation of the Glutathione Redox SystemBlood, 1999
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideThe New England Journal of Medicine, 1998
- Arsenic Trioxide as an Inducer of Apoptosis and Loss of PML/RARα Protein in Acute Promyelocytic Leukemia CellsJNCI Journal of the National Cancer Institute, 1998
- In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteinsBlood, 1996